The American Medical Association (AMA) continues to express its concerns over Walmart's corporate prescription opioid restriction policy in its recent letter to Walmart's Chief Medical and Analytics Officer. The new policy limit opioid prescriptions to seven days or 50 morphine milligram equivalents (MME) has caused harm to patients with acute, palliative, cancer-related, chronic pain and other medical conditions requiring amounts or doses greater than the corporate policy. According to the AMA, "this policy has disrupted legitimate medical practices that receive form letters telling them their prescribing rights under state law will be superseded by a Walmart-created algorithm that deems a physician unfit to prescribe."
The U.S. Department of Health and Human Services (HHS) announced more than $1.8 billion in funding to states to continue the Trump administration's efforts to combat the opioid crisis by expanding access to treatment and supporting near real-time data on the drug overdose crisis.
The World Health Organization (WHO) announces the revision process for two recently discontinued documents: "Ensuring balance in national policies on controlled substances: Guidance for availability and accessibility of controlled medicines" (2011) and "WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses" (2012). A Call for Experts was issued as part of identifying potential members of the guideline development groups.